Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019)

Niagen Bioscience (NAGE) has disclosed Amortization of Deferred Charges for 1 consecutive years, with $294000.0 as the latest value for Q3 2019.

Quarterly Amortization of Deferred Charges changed N/A to $294000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $846000.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $846000.0 for FY2019, N/A changed from the prior year.
Amortization of Deferred Charges for Q3 2019 was $294000.0 at Niagen Bioscience, down from $414000.0 in the prior quarter.
The five-year high for Amortization of Deferred Charges was $414000.0 in Q2 2019, with the low at $138000.0 in Q1 2019.